PTGX
Price
$36.82
Change
+$0.28 (+0.77%)
Updated
Jan 17 closing price
Capitalization
2.19B
59 days until earnings call
SNDX
Price
$13.08
Change
+$0.08 (+0.62%)
Updated
Jan 17 closing price
Capitalization
1.12B
46 days until earnings call
Ad is loading...

PTGX vs SNDX

Header iconPTGX vs SNDX Comparison
Open Charts PTGX vs SNDXBanner chart's image
Protagonist Therapeutics
Price$36.82
Change+$0.28 (+0.77%)
Volume$485.31K
Capitalization2.19B
Syndax Pharmaceuticals
Price$13.08
Change+$0.08 (+0.62%)
Volume$1.14M
Capitalization1.12B
PTGX vs SNDX Comparison Chart
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. SNDX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Hold and SNDX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (PTGX: $36.82 vs. SNDX: $13.08)
Brand notoriety: PTGX and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 65% vs. SNDX: 46%
Market capitalization -- PTGX: $2.19B vs. SNDX: $1.12B
PTGX [@Biotechnology] is valued at $2.19B. SNDX’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 2 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • PTGX’s TA Score: 2 bullish, 4 bearish.
  • SNDX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а +0.57% price change this week, while SNDX (@Biotechnology) price change was -0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

PTGX is expected to report earnings on May 07, 2025.

SNDX is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.19B) has a higher market cap than SNDX($1.12B). SNDX YTD gains are higher at: -1.059 vs. PTGX (-4.611). PTGX has higher annual earnings (EBITDA): 152M vs. SNDX (-296.86M). PTGX has more cash in the bank: 469M vs. SNDX (406M). SNDX has less debt than PTGX: SNDX (854K) vs PTGX (10.9M). PTGX has higher revenues than SNDX: PTGX (324M) vs SNDX (16M).
PTGXSNDXPTGX / SNDX
Capitalization2.19B1.12B197%
EBITDA152M-296.86M-51%
Gain YTD-4.611-1.059435%
P/E Ratio13.44N/A-
Revenue324M16M2,025%
Total Cash469M406M116%
Total Debt10.9M854K1,276%
FUNDAMENTALS RATINGS
PTGX vs SNDX: Fundamental Ratings
PTGX
SNDX
OUTLOOK RATING
1..100
7612
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
4372
SMR RATING
1..100
2298
PRICE GROWTH RATING
1..100
5889
P/E GROWTH RATING
1..100
304
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (63) in the Biotechnology industry is in the same range as SNDX (85). This means that PTGX’s stock grew similarly to SNDX’s over the last 12 months.

PTGX's Profit vs Risk Rating (43) in the Biotechnology industry is in the same range as SNDX (72). This means that PTGX’s stock grew similarly to SNDX’s over the last 12 months.

PTGX's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for SNDX (98). This means that PTGX’s stock grew significantly faster than SNDX’s over the last 12 months.

PTGX's Price Growth Rating (58) in the Biotechnology industry is in the same range as SNDX (89). This means that PTGX’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is in the same range as PTGX (30). This means that SNDX’s stock grew similarly to PTGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXSNDX
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
82%
Bearish Trend 11 days ago
79%
Momentum
ODDS (%)
Bearish Trend 11 days ago
73%
Bullish Trend 11 days ago
86%
MACD
ODDS (%)
Bearish Trend 11 days ago
71%
Bullish Trend 11 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
76%
Bullish Trend 11 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 11 days ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 20 days ago
75%
Bearish Trend 20 days ago
77%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 11 days ago
75%
View a ticker or compare two or three
Ad is loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OIEFX24.090.16
+0.67%
JPMorgan Equity Income R2
BEGRX16.250.09
+0.56%
Franklin Mutual Beacon Z
BIPIX43.910.08
+0.18%
ProFunds Biotechnology UltraSector Inv
FFGRX23.92N/A
N/A
Emerald Growth Investor
VDSRX22.21N/A
N/A
Victory Diversified Stock R6

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with ZYME. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.77%
ZYME - PTGX
41%
Loosely correlated
-0.79%
ACLX - PTGX
39%
Loosely correlated
-0.79%
BEAM - PTGX
39%
Loosely correlated
+0.17%
VRDN - PTGX
38%
Loosely correlated
+6.27%
SNDX - PTGX
38%
Loosely correlated
+0.62%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with ARVN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then ARVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+0.62%
ARVN - SNDX
46%
Loosely correlated
+2.67%
ABOS - SNDX
46%
Loosely correlated
+2.48%
RAPT - SNDX
45%
Loosely correlated
+0.84%
VCYT - SNDX
45%
Loosely correlated
-1.27%
KYMR - SNDX
43%
Loosely correlated
+0.79%
More